Teleflex stock (US8793691069): Q1 earnings beat with revenue up 32%

Teleflex reported Q1 EPS of $1.39, beating estimates by $0.18, with revenue surging 32.3% year-over-year. Shares traded at $129.91 on May 13, 2026.

Teleflex Incorporated released its first-quarter results for 2026, posting earnings per share of $1.39, which exceeded the consensus estimate of $1.21 by $0.18. Quarterly revenue climbed 32.3% from the prior year, according to MarketBeat as of 05/13/2026. Despite the top-line strength, the stock dipped post-earnings due to margin pressures, including a 52.1% drop in operating profit.

The stock traded at $129.91 USD on May 13, 2026, on the NYSE, up 0.68% for the day, according to MarketBeat as of 05/13/2026. Year-to-date, shares have risen 6.4% from $122.07.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Teleflex Incorporated
• Sector/industry: Medical technology
• Headquarters/country: United States
• Core markets: Critical care, surgery
• Key revenue drivers: Medical devices
• Home exchange/listing venue: NYSE (TFX)
• Trading currency: USD

Teleflex: core business model

Teleflex Incorporated develops and manufactures medical technology products focused on critical care and surgical applications. The company provides devices for vascular access, interventional urology, anesthesia, and emergency medicine. Its portfolio includes single-use consumables and capital equipment used in hospitals worldwide.

Teleflex operates through segments like Vascular Access, Interventional, and OEM. These areas drive recurring revenue from disposable products essential to patient procedures. The firm's emphasis on innovation supports its role in acute care settings.

Main revenue and product drivers for Teleflex

Key revenue comes from the Vascular Access segment, featuring Arrow-brand catheters and introducers. Interventional specialties include urology tools like the UroLift system for benign prostatic hyperplasia treatment. OEM supplies components to other medtech firms.

Surgery and Anesthesia products, such as laryngeal masks and pain pumps, contribute significantly. In Q1 2026, overall revenue grew 32.3% year-over-year, reflecting strong demand across these drivers, per MarketBeat as of 05/13/2026.

Industry trends and competitive position

The medical device sector benefits from aging populations and procedural growth in the US. Teleflex competes with players like BD and Medtronic in vascular and urology niches. Its focus on minimally invasive tools aligns with trends toward outpatient care.

Teleflex holds a solid position in niche markets, with the UroLift system gaining share in BPH treatments. US investors track its exposure to elective procedures, which rebounded post-pandemic.

Why Teleflex matters for US investors

Listed on the NYSE, Teleflex offers US investors direct access to a leader in medical consumables. Its products serve major US hospitals, tying performance to domestic healthcare spending, which exceeds 17% of GDP.

With a market cap of $5.75 billion as of May 13, 2026, per MarketBeat as of 05/13/2026, it provides mid-cap exposure to medtech growth without large-cap volatility.

Conclusion

Teleflex delivered a Q1 earnings beat with robust revenue growth, though margins faced headwinds. Analysts maintain a Hold consensus with a $144 target. The company's medtech focus positions it amid US healthcare expansion, warranting monitoring of profitability trends and procedural volumes.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.